BB Medtech Ag

Orion Oyj (HEL:ORN1V) Orion Corporation will publish its 2008 Financial Statement release on Friday, 6 February 2009. The estimated time of disclosure is 12.00 EET. The release and the presentation material will be available after publication on the Group's homepage at www.orion.fi/investors.

Orion Oyj (HEL:ORN1V) In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act, Orion Corporation publishes an Annual Summary of the stock exchange releases and announcements published by the company in 2008. The releases and announcements are available on the internet website of Orion Corporation, at www.orion.fi/investors. Orion points out that part of the information in the releases can have become out-dated.

Orion Oyj (HEL:ORN1V) Company states the realisation of generic competition is neither certain nor imminent

Orion Oyj (HEL:ORN1V) The statutory negotiations which were initiated in Orion Corporation with personnel representatives in November 2008 with emphasis on changes in the operational model and structure of pharmaceutical research and development, have been completed. In result, a decision has been made to reduce the company's personnel in Finland by altogether about 205 persons, of which about 175 will be given a notice and about 30 positions will be terminated through retirement and other arrangements. According to the original estimate, the negotiations could have led to cutting up to 300 jobs. In its financial period Q4/2008, Orion will book a non-recurring charge of preliminarily about EUR 3.9 million relating to the structural rearrangements.

Orion Oyj (HEL:ORN1V) Company states the realisation of generic competition is still neither certain nor imminent

Orion Oyj (HEL:ORN1V) Company states the realisation of generic competition is neither certain nor imminent

Orion Oyj (HEL:ORN1V) Orion Corporation will develop a more flexible and lighter operational model for the pharmaceutical research and development of the company. The statutory negotiations with the personnel representatives are therefore introduced in Finland. The purpose of the negotiations is to achieve a more flexible cost structure and operational model as well as to reduce costs. The rearrangements dealt with in the negotiations are concerning primarily the pharmaceutical R&D, and they may lead to a reduction of the personnel by up to 300 employees. The changes are planned to be implemented in the course of 2009. By reshaping the current operational model and cost structure of the R&D into a more flexible one, Orion prepares for ensuring its prerequisites of doing business as well as its competitiveness even after the expiry of the basic patents protecting its most important products, in the early part of the next decade.

Orion Oyj (HEL:ORN1V) Company states the realisation of generic competition is still neither certain nor imminent

Orion Oyj (HEL:ORN1V) The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company: Kari Jussi Aho Matti Kavetvuo Timo Maasilta Timo Ritakallio Jukka Ylppö.

Orion Oyj (HEL:ORN1V) Orion's net sales in January-September 2008 stood at EUR 530.1 million (1-9/2007: EUR 509.6 million), up by 4.0% on the comparative period of January-September 2007.